Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 605 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 605 shares of Bicara Therapeutics stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $18.15, for a total value of $10,980.75. Following the completion of the transaction, the chief financial officer owned 145,355 shares in the company, valued at $2,638,193.25. This trade represents a 0.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Ivan Hyep also recently made the following trade(s):

• On Monday, November 24th, Ivan Hyep sold 17,795 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.55, for a total transaction of $330,097.25.
• On Thursday, October 9th, Ivan Hyep sold 6,415 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.23, for a total transaction of $116,945.45.
• On Tuesday, October 7th, Ivan Hyep sold 18,244 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total transaction of $332,405.68.
• On Wednesday, October 8th, Ivan Hyep sold 5,627 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.21, for a total transaction of $102,467.67.
• On Monday, October 6th, Ivan Hyep sold 6,514 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.17, for a total transaction of $118,359.38.

Bicara Therapeutics Stock Down 2.2%

Shares of BCAX opened at $18.46 on Wednesday. The company has a 50 day moving average of $15.59 and a two-hundred day moving average of $12.69. Bicara Therapeutics Inc. has a twelve month low of $7.80 and a twelve month high of $22.67. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -8.24 and a beta of -0.76.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). On average, sell-side analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Wells Fargo & Company increased their price target on Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Tuesday, October 14th. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research report on Monday, November 10th. Piper Sandler initiated coverage on shares of Bicara Therapeutics in a research note on Monday, August 18th. They issued an “overweight” rating and a $36.00 target price for the company. Finally, HC Wainwright dropped their target price on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, August 22nd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Bicara Therapeutics has an average rating of “Moderate Buy” and an average target price of $29.67.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BCAX. Vestal Point Capital LP lifted its holdings in shares of Bicara Therapeutics by 80.6% during the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after purchasing an additional 2,231,025 shares during the period. Wellington Management Group LLP raised its position in Bicara Therapeutics by 84.0% during the 1st quarter. Wellington Management Group LLP now owns 1,394,676 shares of the company’s stock worth $18,173,000 after buying an additional 636,708 shares during the last quarter. Bank of America Corp DE raised its position in Bicara Therapeutics by 2,351.0% during the 2nd quarter. Bank of America Corp DE now owns 451,228 shares of the company’s stock worth $4,192,000 after buying an additional 432,818 shares during the last quarter. Artisan Partners Limited Partnership acquired a new stake in Bicara Therapeutics during the 2nd quarter valued at approximately $3,742,000. Finally, Schroder Investment Management Group boosted its holdings in shares of Bicara Therapeutics by 921.0% in the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock valued at $3,951,000 after acquiring an additional 383,681 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.